Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.
Standard
Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. / Goekkurt, Eray; Stoehlmacher, Jan; Stueber, Christian; Wolschke, Christine; Eiermann, Thomas; Iacobelli, Simona; Zander, Axel R.; Ehninger, Gerhard; Kröger, Nicolaus.
In: ANTICANCER RES, Vol. 27, No. 6, 6, 2007, p. 4377-4380.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.
AU - Goekkurt, Eray
AU - Stoehlmacher, Jan
AU - Stueber, Christian
AU - Wolschke, Christine
AU - Eiermann, Thomas
AU - Iacobelli, Simona
AU - Zander, Axel R.
AU - Ehninger, Gerhard
AU - Kröger, Nicolaus
PY - 2007
Y1 - 2007
N2 - THE AIM of this study was to evaluate the impact of genomic polymorphisms of methylene-tetrahydrofolate-reductase (MTHFR-C677T, MTHFR-A1298C) and various glutathione S-transferases (GSTP1-Ilel05Val, GSTA1*a/b, GSTM1, GSTT1) on the occurrence of liver toxicity in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). PATIENTS AND METHODS: Eighty-four adult patients were enrolled in this retrospective study. All patients were treated with busulfan/cyclophosphamide as a conditioning regimen and received cyclosporine and short-course MTX for GvHD prophylaxis. Genotyping was performed using PCR based restriction-fragment-length-polymorphism (RFLP) techniques. RESULTS: Multivariate analysis identified the MTHFR-A1298C polymorphism as an independent predictor for maximum levels of bilirubin (p=0.0025) and duration of hyperbilirubinaemia (p=0.013). Furthermore, there was an association between this polymorphism and the occurrence of the sinusoidal obstruction syndrome (SOS) (p=0.048). No significant associations between the MTHFR-C677T or the various GST polymorphisms and liver toxicity were observed. CONCLUSION: The MTHFR-A1298C polymorphism might be associated with liver toxicity in patients receiving allogeneic HSCT.
AB - THE AIM of this study was to evaluate the impact of genomic polymorphisms of methylene-tetrahydrofolate-reductase (MTHFR-C677T, MTHFR-A1298C) and various glutathione S-transferases (GSTP1-Ilel05Val, GSTA1*a/b, GSTM1, GSTT1) on the occurrence of liver toxicity in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). PATIENTS AND METHODS: Eighty-four adult patients were enrolled in this retrospective study. All patients were treated with busulfan/cyclophosphamide as a conditioning regimen and received cyclosporine and short-course MTX for GvHD prophylaxis. Genotyping was performed using PCR based restriction-fragment-length-polymorphism (RFLP) techniques. RESULTS: Multivariate analysis identified the MTHFR-A1298C polymorphism as an independent predictor for maximum levels of bilirubin (p=0.0025) and duration of hyperbilirubinaemia (p=0.013). Furthermore, there was an association between this polymorphism and the occurrence of the sinusoidal obstruction syndrome (SOS) (p=0.048). No significant associations between the MTHFR-C677T or the various GST polymorphisms and liver toxicity were observed. CONCLUSION: The MTHFR-A1298C polymorphism might be associated with liver toxicity in patients receiving allogeneic HSCT.
M3 - SCORING: Zeitschriftenaufsatz
VL - 27
SP - 4377
EP - 4380
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 6
M1 - 6
ER -
